Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference [Yahoo! Finance]
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
Company Research
Source: Yahoo! Finance
top-line readout in H2 ; the study uses an enrichment design that withdraws IL-1 blockade to increase placebo recurrence and the FDA has granted Orphan Drug Designation for pericarditis. Phase II results showed rapid pain improvement within two weeks (sustained at follow-up), CRP normalized by 26 weeks, and recurrences fell from 5.8 to 0.9 events/year with 71% of patients recurrence-free, supporting CardiolRx as an oral, non-immunosuppressive treatment option. The ARCHER myocarditis trial reported a highly significant 9.2-gram reduction in left ventricular mass and favorable imaging trends, and Cardiol says it is fully funded with CMC readiness while advancing a subcutaneous next-gen candidate (CRD-38) and courting strategic partners for broader opportunities. Interested in Cardiol Therapeutics Inc.? Here are five stocks we like better. 3 Penny Stocks Ready to Break Out in 2025 Cardiol Therapeutics (NASDAQ:CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Confer
Show less
Read more
Impact Snapshot
Event Time:
CRDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDL alerts
High impacting Cardiol Therapeutics Inc. - Class A Common Shares news events
Weekly update
A roundup of the hottest topics
CRDL
News
- Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.MarketBeat
- Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.MarketBeat
- Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long [Yahoo! Finance]Yahoo! Finance
CRDL
Analyst Actions
- 2/10/26 - HC Wainwright
CRDL
Sec Filings
- 2/25/26 - Form 6-K
- 2/10/26 - Form 6-K
- 2/2/26 - Form 6-K
- CRDL's page on the SEC website